These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33230386)

  • 21. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.
    Glinsky GV
    Biomedicines; 2020 May; 8(5):. PubMed ID: 32455629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tackling SARS-CoV-2: proposed targets and repurposed drugs.
    Joshi S; Joshi M; Degani MS
    Future Med Chem; 2020 Sep; 12(17):1579-1601. PubMed ID: 32564623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
    Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
    J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.
    Mslati H; Gentile F; Perez C; Cherkasov A
    J Chem Inf Model; 2021 Aug; 61(8):3771-3788. PubMed ID: 34313439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2.
    Niranjan V; Setlur AS; Karunakaran C; Uttarkar A; Kumar KM; Skariyachan S
    Struct Chem; 2022; 33(5):1585-1608. PubMed ID: 35938064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
    Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM
    PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
    Zhou Y; Hou Y; Shen J; Huang Y; Martin W; Cheng F
    Cell Discov; 2020; 6():14. PubMed ID: 32194980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid Identification of Druggable Targets and the Power of the PHENotype SIMulator for Effective Drug Repurposing in COVID-19.
    Maria NI; Rapicavoli RV; Alaimo S; Bischof E; Stasuzzo A; Broek JAC; Pulvirenti A; Mishra B; Duits AJ; Ferro A
    Res Sq; 2021 Apr; ():. PubMed ID: 33880466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing.
    Maria NI; Rapicavoli RV; Alaimo S; Bischof E; Stasuzzo A; Broek JAC; Pulvirenti A; Mishra B; Duits AJ; Ferro A;
    Heliyon; 2023 Mar; 9(3):e14115. PubMed ID: 36911878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
    Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
    Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.
    Islam T; Rahman MR; Aydin B; Beklen H; Arga KY; Shahjaman M
    Eur J Pharmacol; 2020 Nov; 887():173594. PubMed ID: 32971089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex.
    Matschinske J; Salgado-Albarrán M; Sadegh S; Bongiovanni D; Baumbach J; Blumenthal DB
    Assay Drug Dev Technol; 2020; 18(8):348-355. PubMed ID: 33164550
    [No Abstract]   [Full Text] [Related]  

  • 36. Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages.
    Wang X; Wang H; Yin G; Zhang YD
    Heliyon; 2023 Mar; 9(3):e14059. PubMed ID: 36855680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL
    Eberle RJ; Olivier DS; Amaral MS; Gering I; Willbold D; Arni RK; Coronado MA
    Viruses; 2021 May; 13(5):. PubMed ID: 34068686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model.
    Chen YT; Chang YH; Pathak N; Tzou SC; Luo YC; Hsu YC; Li TN; Lee JY; Chen YC; Huang YW; Yang HJ; Hsu NY; Tsai HP; Chang TY; Hsu SC; Liu PC; Chin YF; Lin WC; Yang CM; Wu HL; Lee CY; Hsu HL; Liu YC; Chu JW; Wang LH; Wang JY; Huang CH; Lin CH; Hsieh PS; Wu Lee YH; Hung YJ; Yang JM
    Front Immunol; 2022; 13():1080897. PubMed ID: 36618412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    More SA; Patil AS; Sakle NS; Mokale SN
    Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.